RAGE Signalling in Acute Inflammatory Disorders: Therapeutic Potential of Natural Products.
Level 5 - mechanism / opinion, no new human data
Narrative review of molecular mechanisms and preclinical natural compounds without clinical trial data
PubMed 42509722 · doi:10.3390/biom16070929
What was done
This narrative review summarizes molecular mechanisms of receptor for advanced glycation end-products (RAGE) signaling in acute inflammatory disorders (including acute lung injury, acute pancreatitis, ischemia-reperfusion injury, and sepsis) and outlines the therapeutic potential of natural product classes such as terpenoids, flavonoids, alkaloids, and a xanthone.
What was found
The abstract reports no quantitative values, effect sizes, or study counts. It describes qualitative pathways showing that RAGE activation drives downstream NF-κB and MAPK signaling to worsen hyperinflammation, and notes that specific natural bioactive molecules disrupt RAGE-ligand binding, oxidative stress, and cytokine release.
Why it matters
Modulating RAGE represents a potential strategy to prevent cytokine storms and organ failure in acute inflammatory states, with natural products serving as potential alternative chemical scaffolds.
Limits
The review provides no quantitative data, primary human clinical trials, or systematic search methodology in the abstract. Clinical efficacy, pharmacokinetics, and safety of these natural compounds in patients remain unestablished.
Cited by
- supports Glycated proteins are highly inflammatory in the human body.